GF SECURITIES·2025-12-30 02:13Investment Rating - The industry investment rating is "Buy" [2] Core Insights - The report highlights that the artificial cultivation of Cordyceps sinensis is reshaping the industry, with traditional sectors giving rise to new opportunities [1] - The market for artificial Cordyceps is expected to grow due to its price advantage and increasing consumer demand for health products [1] - The report emphasizes the importance of technological advancements in artificial cultivation to overcome challenges and enhance production efficiency [1] Summary by Sections Section 1: Overview of Cordyceps Sinensis - Cordyceps sinensis, primarily sourced from the Tibetan Plateau, has an industry scale of nearly 400 billion CNY, with a recent decline in wild collection due to ecological and policy constraints [15][16] - The average price of Cordyceps reached a peak of over 220,000 CNY per kilogram in 2013, but has since fluctuated, currently averaging 190,000 CNY per kilogram as of November 2025 [15][36] Section 2: Decline in Wild Collection and Challenges in Artificial Cultivation - The collection of wild Cordyceps has decreased, with an estimated 85 tons harvested in 2023, a 23% decline from 2019 [44] - Artificial cultivation faces high technical barriers, including the need for stable infection rates and complex production processes [48] Section 3: Reshaping the Industry through Scaled Artificial Cultivation - The industry is transitioning towards a dual structure of "wild premium + artificial substitutes," with artificial Cordyceps gaining traction in the health market [55] - Major companies are investing in factory-based cultivation, with significant projects announced by Zhongxing Junye and Xuelong Biological [59][60] Section 4: Investment Recommendations - The report recommends focusing on Zhongxing Junye and Xuelong Biological, which are actively expanding into the factory-based cultivation of Cordyceps [59][60]